TreatSMA families take SMA cause to the Parliament

Today a group of TreatSMA families attended a meeting of the All-Party Parliamentary Group for Muscular Dystrophy at the House of Lords.

The meeting was chaired by Mary Glindon, MP and was organised by Muscular Dystrophy UK. Other than 10 TreatSMA families, present were also other peers, SMA Support UK, SMA Trust, doctors, representatives of the NHS and officials from the Great Ormond Street Hospital in London.

The meeting was about access to treatment. TreatSMA families, many of whom travelled from far away, talked about their living experiences of SMA. It was hard to fight back tears.

It is necessary that our cause is heard loud and clear on the decision-making level at the Parliament and Government. Today’s meeting was an important step in our struggle for treatment for all.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more